Literature DB >> 21856109

The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC.

Hongbin Chen1, Yudong Liu, Wenjia Sun, Minjun Chen, Hui Wang.   

Abstract

A total of 559 methicillin-resistant Staphylococcus aureus isolates were investigated for heterogeneous vancomycin-intermediate S. aureus (hVISA) by population analysis profile area under the curve. Our results suggested that the incidence of hVISA increased rapidly when vancomycin MIC shifted from 1 to 2 μg/mL, and at vancomycin MIC of 2 μg/mL, the incidence of hVISA was nearly 40%.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856109     DOI: 10.1016/j.diagmicrobio.2011.06.010

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

Review 1.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

2.  Vancomycin MIC and agr dysfunction in invasive MRSA infections in southern Brazil.

Authors:  Adriana Medianeira Rossato; Muriel Primon-Barros; Cícero Armídio Gomes Dias; Pedro Alves d'Azevedo
Journal:  Braz J Microbiol       Date:  2020-10-19       Impact factor: 2.476

3.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 4.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.